Home » Cutaneous T-cell lymphoma, the first results of the PROSPER study on mogalizumab presented

Cutaneous T-cell lymphoma, the first results of the PROSPER study on mogalizumab presented

by admin
Cutaneous T-cell lymphoma, the first results of the PROSPER study on mogalizumab presented

The real life observational investigation aims to analyze the impact of treatment with the drug in patients suffering from the two most common subtypes of the disease

Milan – The pharmaceutical company Kyowa Kirin presented i first real life results of the PROSPER study at the 5th Annual Meeting of the World Cutaneous Lymphoma Congress in Pasadena, California, which highlighted thepositive impact of mogamulizumab in patients with cutaneous T-cell lymphoma (CTCL)a rare, sometimes serious and life-threatening form of non-Hodgkin lymphoma.

CTCL accounts for approximately 4% of all non-Hodgkin lymphoma cases and up to 80% of all primary cutaneous lymphomas. In advanced disease, malignant T cells can spread to the lymphatic system, blood, bone marrow and internal organs. Therefore, it can have a profound impact on the quality of life related to the health and psychological well-being of patients.

Lo studio PROSPER is a prospective observational survey conducted in six countries across Europe, North America and the Middle East. Of these, Italy is the country with the most centers involved in the studysix, in cities such as Ancona, Bologna, Florence, Milan and Rome (with 2 centres).

With a follow-up of up to 50 weeks after patients entered the study, the objective of the study is to analyze the impact of the drug in patients with mycosismgoid fungi (FM) and Sézary syndrome (SS), the two best-known subtypes of CTCL. To analyze their symptoms and health-related quality of life (HRQoL), researchers collected information from patients and caregivers about their treatment experience.

In particular, The researchers analyzed symptom data collected from the first 20 patients involved in the study, eight with mycosis Fungoides and twelve with Sézary syndrome during the first 16 weeks of therapy. Before starting treatment, patients reported a high burden of symptoms on a numeric scale of 1 to 10, including skin itching (6.6), skin redness (6.2), skin peeling (5.9) and skin pain (4.0). Additionally, more than half of patients reported having sleep problems “frequently” or “every night,” while 47% reported difficulty regulating body temperature “frequently” or “always.”

See also  Tax on bank extra profits, what the law approved by the Council of Ministers provides

Four weeks after starting treatment, an improvement in all symptoms was reported. At week 16, the severity of symptoms decreased considerably, with marked improvement observed inredness of the skin (-2.9), followed by skin itching (-2,7), skin flaking (-2,5) e skin pain (-2.2). Notably, the percentage of patients who reported sleep problems or difficulty regulating body temperature, “frequently” or “always,” decreased to less than 20%.

“We know that not only do CTCL patients suffer from the stress of a cancer diagnosis, but that this stress is exacerbated by visual impairment and varying levels of discomfort and fatigue,” says one of the study’s Principal Investigators, Dr. Professor Julia Scarisbrick, from the University of Birmingham. “The PROSPER study is helping us better understand these critical issues and the impact that mogamulizumab can have on patients’ symptoms and quality of life.”

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy